summari track im sale perform key
product us inject anesthesia advanc surgeri
net-net im analysi point like in-lin perform us
inject potenti upsid us anesthesia recent
acquisit preveleak recothrom howev
suffici data complet analysi us advanc surgeri
within us inject expect solid perform
cyclophosphamid due continu absenc addit
gener competit brevibloc due on-going suppli
constraint compet drug anesthesia see potenti
upsid driven particularli strong perform transderm
scop like due recent competit suppli issu overal
believ bax compar well vs street expect
base manag recent public comment would caveat
im analysi focus top product im sale
im sale fluctuat especi short-term
said believ analysi still use track
busi togeth repres bax ww sale
us inject busi like in-lin expect
base april-may actual im sale estim im sale
june histor third month account sale
quarter estim us inject im sale
clari figur im sale histor captur
report combin bax/clari us inject sale appli
metric estim im sale yield clari sale
close estim within us inject
expect solid perform brevibloc due continu
shortag calcium channel blocker cyclophosphamid
yet face addit gener competit us inject
clari account one-third ww pharmaceut
revenu total ww revenu
compani data secur llc estim reuter
adjust spin-off baxalta
compani prioriti stock list
compani data secur llc estim reuter
brevibloc perform like strong recal im
data show yr/yr growth us brevibloc sale
due suppli shortag diltiazem also use
treat angina updat ashp american societi
health-system pharmacist websit suggest
shortag abat somewhat suppli constraint remain due
manufactur issu increas demand extrapol im
sale brevibloc total yr/yr increas much
shortag expect resolv summer
linger constraint could benefit bax brevibloc sale
lesser extent im sale clari norepinephrin also suggest
yr/yr sale growth remain robust vs
extrapol norepinephrin im sale vs
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
continu previou page
potenti modest upsid us cyclophosphamid forecast forecast us cyclo sale
yr/yr declin compar extrapol im sale total
yr/yr declin vs im sale captur report cyclophosphamid
sale figur appli captur rate suggest us cyclo sale could
estim magnitud upsid warrant rais forecast guid full year
us cyclo sale nearli yr/yr declin assum two new gener competitor emerg
year new competitor far see bax cyclo sale guidanc conserv
us cyclo sale account ww inject revenu total revenu
potenti upsid us anesthesia sale led transderm scop base april-may actual im
sale extrapol im sale june estim us anesthesia sale
estim figur histor im sale captur bax us anesthesia sale
appli midpoint histor captur rate impli report sale
estim notabl outperform transderm scop im sale growth
yr/yr increas q/q note competitor launch gener version
announc suppli disrupt call expect return market im sale data
march-may seem suggest nv benefit prgo suppli issu
benefit go believ transderm scop tailwind persist
year supran sale appear flattish sequenti continu declin yr/yr us
anesthesia account ww sale
gener supran competit yet despit approv earlier year although fda approv
first gener supran shanghai hengrui late februari product yet reach
market possibl compani still await approv vapor administ
gener drug place vapor hospit expens contract hospit
specifi vapor use specifi product believ
gener convers could slow take time place gener vapor hospit
time gener supran unclear although media report cite anoth competitor piram
target launch gener supran year im sale show us supran sale fell
ytd may accord im supran account bax us anesthesia sale
addit product creat new base us advanc surgeri base april-may actual
im sale estim im sale june estim us advanc surgeri revenu
estim figur histor im sale captur bax report
us advanc surgeri sale howev captur rate like applic addit
preveleak recothrom late march especi preveleak report im recothrom im
sale appear flat yr/yr extrapol im sale floseal fell
understand lose share jnj surgicel believ
im also report product due mostli hospit channel distribut note despit
im sale product declin sinc report us advanc surgeri sale larg
stabl slightli declin us advanc surgeri account ww sale
product totaly/i totaly/i totaly/i chg inj sale clari sale gener inj clari gener inj sale im health inc compani report secur llc estim
price target nc
price target base equal weight ev/ebtida dcf price-to-earnings risk
thesi includ unexpect competit headwind could slow restructur effort signific delay new
believ acceler sale growth expand oper margin consist deliv
reliabl low double-digit ep growth strong balanc sheet could enhanc long-term growth
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
cyclophosphamid report sales/our im health inc compani report secur llc estim product totaly/i totaly/i totaly/i chg anesthesia sale anesthesia sale im health inc compani report secur llc estim product totaly/i totaly/i totaly/i chg adv surgeri sale im adv surgeri sale im health inc compani report secur llc estim medic technolog
